Detalles de la búsqueda
1.
Synchronous occurrence of primary cutaneous B-cell lymphoma and cutaneous Rosai-Dorfman disease in distinct lesions: A unique association.
J Cutan Pathol
; 51(1): 7-10, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36636954
2.
Association between maternal dupilumab exposure and pregnancy outcomes in patients with moderate-to-severe atopic dermatitis: A nationwide retrospective cohort study.
J Eur Acad Dermatol Venereol
; 2024 Jan 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-38284131
3.
Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment.
J Dtsch Dermatol Ges
; 22(1): 34-42, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37926830
4.
Long-term psychological outcome of patients with moderate-to-severe atopic dermatitis continuously treated with Dupilumab: Data up to 3 years.
Exp Dermatol
; 32(6): 852-858, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36856013
5.
The Limitation of Accessing Hospital Services Due to COVID-19 Pandemic: A Pilot Study of the Telephone Triage to Re-Organize the Access to a Center for Sexual Health in Northwest Italy.
Sex Transm Dis
; 50(9): 603-606, 2023 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36728659
6.
Impact on health-related quality of life and symptoms of anxiety and depression after 32 weeks of Dupilumab treatment for moderate-to-severe atopic dermatitis.
Dermatol Ther
; 35(5): e15407, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35218275
7.
Paradoxical psoriasiform reactions during treatment with adalimumab for hidradenitis suppurativa: Real-life experience and therapeutic response to other biological drugs.
Dermatol Ther
; 35(12): e15866, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36175129
8.
Guselkumab shows high efficacy and maintenance in the improvement of response until week 48, a real-life study.
Dermatol Ther
; 35(10): e15670, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35762118
9.
Topical cyclosporine hydrogel preparation: A new therapeutic option in the treatment of nail psoriasis.
Dermatol Ther
; 35(12): e15917, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36214268
10.
Risankizumab shows high efficacy and maintenance in improvement of response until week 52.
Dermatol Ther
; 35(5): e15378, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35156278
11.
Cutaneous side effects and types of dermatological reactions in metastatic melanoma patients treated by immunotherapies or targeted therapies: A retrospective single center study.
Dermatol Ther
; 35(6): e15492, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35384181
12.
Risk of Reactivation of Latent Tuberculosis in Psoriasis Patients on Biologic Therapies: A Retrospective Cohort from a Tertiary Care Centre in Northern Italy.
Acta Derm Venereol
; 102: adv00821, 2022 Nov 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-36065745
13.
Prognostic and Predictive Biomarkers in Stage III Melanoma: Current Insights and Clinical Implications.
Int J Mol Sci
; 22(9)2021 Apr 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-33925387
14.
Dupilumab in HIV-positive patients with atopic dermatitis: a long-term follow-up patient and a literature review.
Dermatol Online J
; 27(8)2021 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34755964
15.
Clinical outcomes and management of JAK inhibitor-associated acne in patients with moderate-to-severe atopic dermatitis undergoing upadacitinib: A multicenter retrospective study.
J Am Acad Dermatol
; 90(5): 1031-1034, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38199282
16.
Secondary laryngeal and pulmonary syphilis: A case report.
J Eur Acad Dermatol Venereol
; 2024 Feb 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-38372430
17.
Safety of dupilumab in patients with cancer.
J Eur Acad Dermatol Venereol
; 2024 Feb 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-38372448
18.
Comparison between brodalumab, secukinumab and ixekizumab effectiveness and drug survival: A real-life experience on 638 patients with psoriasis.
Exp Dermatol
; 32(9): 1591-1594, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37395012
19.
"Superresponders" at biologic treatment for psoriasis: A comparative study among IL17 and IL23 inhibitors.
Exp Dermatol
; 32(12): 2187-2188, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36541075
20.
Drug Survival of Anti Interleukin-17 and Interleukin -23 Agents after Adalimumab Failure in Hidradenitis Suppurativa: A Pilot Study.
Acta Derm Venereol
; 103: adv5278, 2023 04 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-37073963